Astel­las wins pri­or­i­ty re­view for AML drug; Take­da share­hold­ers re­volt against $62B Shire deal

→ Astel­las has won a pri­or­i­ty re­view for its FLT3 drug gilter­i­tinib for treat­ing acute myeloid leukemia. The Japan­ese phar­ma com­pa­ny, which has been earn­ing some added at­ten­tion as a pos­si­ble takeover tar­get, says the fast-paced FDA re­view was based on da­ta from its on­go­ing piv­otal study. A mar­ket­ing de­ci­sion is due No­vem­ber 29. The ther­a­py al­so has Japan’s Saki­ga­ki des­ig­na­tion.

→ A group of Take­da share­hold­ers has been ag­i­tat­ing for a vote on the $62 bil­lion Shire takeover. They say that the buy­out will dam­age Take­da, but the board is op­posed to the vote and wants to see the deal go through.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.